Bard Shannon Limited
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
12
Ending by 2030
Dec 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 2 to 30, 2026 · next Dec 2
- 2 fees due Mar 19, 2027
- 1 fee due May 5, 2027The maintenance fee for Apparatus for the percutaneous marking of a lesion (US 10,463,446) comes due May 5, 2027. Unpaid by Nov 5, 2027, it lapses early.
- 5 fees due Jun 19, 2027
- 2 fees due Jul 30, 2027
- 1 fee due Aug 16, 2027The maintenance fee for Method of mending a groin defect (US 9,259,304) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.
- 1 fee due Sep 24, 2027The maintenance fee for Internal long term absorbable matrix brassiere and tissue engineering scaffold (US 10,595,986) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for In vivo tissue engineering devices, methods and regenerative and cellular medicine employing scaffolds made of absorbable material (US 11,969,337) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,722,039 | Gelatin-transglutaminase hemostatic dressings and sealants In force · From the USPTO record | In force | From the USPTO record | |
| US 9,636,433 | Gelatin-transglutaminase hemostatic dressings and sealants In force · From the USPTO record | In force | From the USPTO record | |
| US 9,655,988 | Gelatin-transglutaminase hemostatic dressings and sealants In force · From the USPTO record | In force | From the USPTO record | |
| US 8,052,658 | Drug-eluting tissue marker In force · From the USPTO record | In force | From the USPTO record | |
| US 8,703,117 | Cross-linked compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 9,044,456 | Cross-linked compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 8,367,388 | Cross-linked compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 9,017,664 | Gelatin-Transglutaminase Hemostatic Dressings and Sealants In force · Medium confidence | In force | Medium confidence | |
| US 10,463,446 | Apparatus for the percutaneous marking of a lesion In force · From the USPTO record | In force | From the USPTO record | |
| US 8,133,484 | Hemostatic materials and dressing In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 37: 1 patent in force now held by others · 4 lapsed for an unpaid fee · 8 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 no status recorded